Azathioprine (Imuran) is one of the most widely used immunosuppressants. Chemical studies have shown that the metabolism of the drug is complex: more than ten metabolites have been isolated and it is thought that more exist. The role of each metabolite present in serum in the biological activity of azathioprine and the interactions between them have not been determined. Bioassays provide an index of the activity present in the serum after drug administration. Chemical methods are usually preferred to bioassays for evaluation of the serum concentration of drugs because bioassays generally do not discriminate between metabolites, and the significance of the activity evaluated is thus difficult to assess. However, when chemical methods are not available, reproducible serum bioassays may prove useful for the clinical management of drugs in normal and pathological conditions, as has been demonstrated extensively for antibiotics.
We have proposed (Bach, Dardenne & Fournier 1969 ) the rosette inhibition test as a precise and RIA sensitive in vitro bioassay for immunosuppressive agents. This assay is based on the inhibition by such agents of rosette formation by normal lymphocytes. The present paper reviews the data obtained using this assay for azathioprine in normal subjects and in patients with liver diseases. We showed in 6 cases that no rosette-inhibiting activity (RIA) appeared in the serum of patients with,severe liver disease after azathioprine administration. In this paper we have extended our study to 18 subjects with various liver diseases, and compared the results with those obtained in normal subjects. The blood level of 35S-labelled azathioprine was studied in 6 normal subjects and in 6 patients with liver diseases along with the rosette inhibition test. Recently, Mitchell et al. (1970) have confirmed our findings in patients with, hepatic failure after liver transplantation.
Material and Methods
Determination of serum RIA: Serum samples are heated to 56°C for 30 min and absorbed with sheep red blood cells to eliminate natural antisheep haemagglutinins which prevent accurate microscopic evaluation of the rosettes. Such absorption does not modify the RIA. Reproducibility is good (Fig 1) : repeated RIA evaluations on one sample are always within one log2 dilution of the mean. We have recently used a simpler method to remove heemagglutinins, which is to filter the serum samples on an Amicon ultrafilter (cut-off=50,000 mol. wt.). No differences have been found between RIAs measured after filtration or absorption.
Kinetics of 35S-labelled azathioprine: 35S-labelled azathioprine (kindly donated by Dr G B Elion, Burroughs Wellcome, North Carolina) was used in some of the subjects (7 normal subjects, 4 patients with cirrhosis, 3 with hepatitis). The specific activity was 2,100 d/min per ,ug; 100 pCi was administered orally in all cases and carriercold azathioprine was added for each dose (3 mg/kg). The radioactivity of serum samples was determined, taking into account the quenching of the preparation.
Patients: Sixteen normal subjects and 19 patients with liver diseases took orally 3 mg/kg per day azathioprine in a single dose. The serum was collected before and at several periods after drug administration (15 min, 30 min, 1, 2, 4, 12, 24 and 48 h). The RIA and the radioactivity (when 35Slabelled azathioprine was used) were determined for each sample. In 3 normal subjects and in 3 patients with liver diseases, 6-mercaptopurine (6-MP) was given at a dose of 1-5 mg/kg. The patients with liver diseases included: 9 cirrhosis, 4 acute hepatitis, 2 chronic hepatitis, 2 hepatitis under azathioprine treatment for a kidney transplantation, and one case of obstructive jaundice without hepatic disease. Seven of the 9 patients with cirrhosis were in poor clinical condition with prothrombin times under 60 %, bilirubin 1 2-4 0 mg/100 ml and hypergammaglobulinmmia; but transaminase activities (SGOT and SGPT) were normal. Alkaline phosphatase was elevated in 4 cases. In 6 cases liver biopsy showed severe cirrhosis, and 4 of these patients died within six months. In 3 cases of acute hepatitis the SGOT and SGPT were over 500 u/ml and the bilirubin over 3-0 mg/100 ml. In the fourth case, at the recovery stage, SGOT was 200 u/ml and bilirubin 2 2 mg/100 ml. Two patients had chronic active hepatitis with icterus, bilirubin over 4 0 mg/100 ml and SGOT and SGPT over 800 u/ml. Diagnosis was confirmed by liver biopsy. Prothrombin times and cholesterol were normal. In the 2 patients with kidney transplants hepatitis was mild. In the first case the SGOT was normal, the bilirubin level was over 5 2 mg/100 ml and the alkaline phosphatase was raised. In the second case the SGOT was 110 u/ml and the bilirubin and alkaline phosphatase were normal.
Results
Normal subjects ( Fig 2) : RIA can be detected at a significant level in the serum after oral administration of 3 mg/kg azathioprine. The values of RIA as well as of-35S activity vary from one subject to another, but the general pattern is that 35S activity appears at a high level in the serum 15 min after administration of the drug and reaches its maximum 30-60 min later. Serum RIA appears after 30 min and reaches its maximum (1) Azathioprine:
In 11 patients with severe liver dysfunction (Fig 3) no RIA was observed after oral or i.v. administration of azathioprine. In 5 subjects-with slight liver dysfunction some RIA was observed one hour after azathioprine administration, but in 3 of these patients activity was significantly lower than in normal subjects (P<0 01). In 2 of these patients a delay was observed in the disappearance of the activity. In another patient recovering from acute hepatitis, the RIA developed at a normal rate and level,but its disappearance was significantly delayed. Serum RIA was normal in a patient with severe obstructive jaundice.
(2) 6-Mercaptopurine: Two normal subjects and 3 subjects with liver disease were studied after oral administration of 1*5 mg/kg 6-MP. In 2 of these 3 subjects the azathioprine curves had already been established. In normal subjects 1-5 mg/kg 6-MP gave serum RIA not significantly different from that obtained with 3 mg/kg azathioprine. The results with 6-MP in liver patients were identical with those found when using azathioprine in the sarne patients.
Metabolism of 35S-labelled azathioprine in liver diseases (Figs 3 & 4):
There was no significant difference in the shape of the. curves Of 35S metabolism obtained in normal subjects and:in patients with liNver disease. The peak-was observed after 30-60 min. The 35S was almost entirely eliminated after 24 h. A greater spread of results was observed in patients with liver disease than in normal subjects, probably due to the higher bilirubintemia and to serum biochemical modifications in liver patients which interfere with counting. Figs 2-4 show representative curves in normal subjects and in liver patients.
Studies in vitro on sera from liver patients: Serum samples from a cirrhotic patient taken before and 2 hours after azathioprine administration (no detectable RIA) were mixed with a serum sample taken from a normal subject one hour after azathioprine intake (RIA = 1/64). The RIA was not affected. The same serum was incubated with mouse red cells (4 ml red cells to 0 5 serum for 60 min at 37°C). After this incubation, known to increase the RIA induced by 1 ng native azathioprine (Bach & Dardenne 1970) , there was still no detectable RIA.
Discussion
The significance of RJA must be discussed first. It is not possible to correlate any assay with serum immunosuppressive activity because the latter concept is too ill-defined. In other words, knowledge of the mechanism of immunosuppression at the cellular level is insufficient to allow direct assay. However, a number of arguments suggest that RIA is related to immunosuppressive activity: (1) the cells used in this test are small lymphocytes involved in the immune response at the stage of antigen recognition (Bach et al. 1970) ; (2) a good correlation has been found between the RIA in vitro of antilymphocyte serum (Bach, Dardenne, Dormont & Antoine 1969; Bach, Dormont, Dardenne & Balner 1969) and immunosuppressive drugs (Bach, Dardenne & Foumier 1969) and their immunosuppressive activity in vivo; this correlation suggests that rosette inhibition may be relevant to the mode of action in vivo of these agents (Bach 1971 , Laborde & Bach 1971 ; (3) serum metabolites of azathioprine can be detected by their inhibition of the mixed lymphocyte reaction, and the serum kinetics of metabolites detected by this method are identical with those of rosette-inhibiting metabolites (Laborde & Bach 1971) . As mixed lymphocyte reaction represents an immunological reaction, the parallelism between metabolites inhibiting mixed lymphocyte reaction and rosette-inhibiting metabolites strongly suggests that the latter are related to immunosuppressive activity.
Our studies provide some information regarding azathioprine metabolism. Azathioprine is absorbed very rapidly (15-30 min) and extensively, but must be metabolically transformed before it becomes active. Activation takes 60-120 min since the serum RIA peak is not observed until 60 min after azathioprine has been administered orally or i.v. Such activation needs hypoxanthineguanine-phosphoribosyl-transferase since no serum RIA was found in a patient with this enzyme deficiency (Bach & Dardenne 1970) . Azathioprine is mainly eliminated by the kidney although very little unmodified azathioprine or 6-MP is found in urine (Elion 1967) . The relative unimportance of renal elimination is confirmed by the normal serum RIA found in renal failure (Bach & Dardenne 1971) in contrast with the abnormal 35S kinetics. If renal elimination does not play a major role in serum disappearance, such disappearance must be due to rapid and extensive degradation.
The absence of azathioprine serum RIA in liver patients is more difficult to explain. We shall first consider experiments which eliminate a number of hypotheses. (1) Since serum RIA is absent whether the drug is given i.v. or orally, there is no defect in intestinal absorption. Normal 35S metabolism in these patients also eliminates a possible abnormality in absorption.
(2) Moreover, it shows that the distribution volume of the drug is not significantly different from that in normal subjects if it is assumed that azathioprine is not appreciably degraded before intestinal absorption.
(3) No inhibiting factor is present in the serum of liver patients, as shown by mixing serum from normal subjects and from liver patients taken one hour after administration of the drug. However, one cannot exclude the possibility that biochemical changes in liver diseases modify RIA. (4) Hyperbilirubinmmia does not interfere with azathioprine metabolism since this was normal in the case of obstructive jaundice, although it may interfere with 35S measurement. (5) The fact that a similar abnormality has been found in patients treated with 6-MP shows that the metabolic alteration does not consist primarily in the failure of conversion of azathioprine into 6-MP.
The mechanism of the abnormality of the RIA curves in patients with liver diseases has not yet been determined. The curves are extremely abnormal, both in cases of severe hepatic dysfunction with little inflammatory process (e.g. liver cirrhosis) and in cases with predominant inflammation (i.e. with increase of SGPT level). Moderately severe cases are sometimes associated with significant modifications of the curves and mild cases seem to be associated with normal RIA. Information about azathioprine metabolism has been reviewed by Elion (1967) . Existence in vivo of a metabolic activation of azathioprine is proved by the fact that in normal subjects the peak of the curves after administration of the drug is higher than that expected if no activation occurred (Bach, Dardenne & Fournier 1969) . Drug degradation would interfere with activation under the influence of xanthine oxidase. In view of these metabolic considerations, the absence of RIA in liver diseases may be due either to an activation defect or to excessive degradation. If the abnormality in azathioprine metabolism in liver disease is a failure of activation due to enzymatic deficiency, this probably does not involve red cell enzymes because mouse red cells do not restore activity to the sera of liver patients. A non-enzymatic liver deficiency may also be possible since liver homogenates can split azathioprine in vitro after removal of trichloroacetic precipitable proteins or heating up to 100°C for 15 min (Bresnick 1959) .
Excessive degradation could be due to an abnormally high level of catabolizing enzyme in the sera of patients with liver disease, as occurs with transaminase and xanthine oxidase (Bockus 1965) . Azathioprine might be degraded, for example, by xanthine oxidase immediately after activation, thus preventing any increase in active metabolites in the serum. However, the fact that serum from liver patients contains no inhibiting factor for the activity present in normal subjects after administration of azathioprine is against this hypothesis. Moreover, high SGPT and SGOT levels were not found in cirrhotic patients.
The metabolic abnormality of azathioprine described above can be discussed in terms of the results of clinical trials. Toxicity must be considered separately from immunosuppressive efficiency. Leukopenias have been observed by several authors during azathioprine treatment of chronic hepatitis or cirrhosis (MacKay et al. 1964 , Geenen et al. 1966 , Ranek et al. 1970 ; in these cases the inflammatory process was markedly predominant over cellular failure. Conversely, no leukopenias were observed in the series of Terrasse et al. (1967) , who treated cirrhotic patients with 6-MP at doses higher than 3 mg/kg/ day for several weeks.
However, it should be emphasized that metabolites toxic to bone marrow are not necessarily identical with immunosuppressive metabolites and Elion et al. (1963) have shown that in the mouse allopurinol treatment increases the 6-MP toxicity twofold and the immunosuppressive activity fourfold. Clinical improvement has been reported in chronic hepatitis treated with azathioprine, but corticosteroids are also active in this disease and it is uncertain whether the action of azathioprine in chronic hepatitis is due to immunosuppression or to an anti-inflammatory action. Moreover, the only controlled clinical trial published (Soloway et al. 1971 ) has reported a lack of clinical activity of azathioprine in chronic liver disease. Valid clinical data are also available in liver transplantation. Starzl et al. (1969) first obtained good results in human liver transplants when using ALS associated with azathioprine and observed rejection crises immediately after stopping ALS treatment. These rejection crises were reversible when ALS was given again. Similarly, with azathioprine alone Moore et al. (1964) did not obtain good liver graft survival prolongation in the dog, in contrast with good prolongation obtained with ALS (Birtch & Moore 1969 ). As Mitchell et aL. (1970) indicate, our data seem to throw light on the problem of the poor activity of azathioprine in cases of liver failure after transplantation. Azathioprine should probably be used together with other immunosuppressive agents in the prevention of rejection in liver transplantation. Furthermore, the indications for the use of azathioprine in liver disease should be reconsidered in view of our findings.
